M. Kawashima, I. Kurokawa, Nobukazu Hayashi, Masako Watanabe, M. Tanioka
{"title":"Which drug do you choose to treat various symptoms of acne vulgaris? (second report) - a proposal for cases in which initial treatment was not successful -","authors":"M. Kawashima, I. Kurokawa, Nobukazu Hayashi, Masako Watanabe, M. Tanioka","doi":"10.3812/jocd.36.46","DOIUrl":"https://doi.org/10.3812/jocd.36.46","url":null,"abstract":"","PeriodicalId":17355,"journal":{"name":"Journal of The Japan Organization of Clinical Dermatologists","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72811136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Imafuku, Bunji Koga, K. Itou, H. Ihara, T. Kamiya, Kinya Takagaki, Nobutaka Kusaba
Psoriasis is a chronic inflammatory skin disease. While the etiology of psoriasis is not yet clear, environme-ntal factors such as food or eating habits are considered important aspects. Pine bark extract (Flavangenol Ⓡ ) is a polyphenol-rich antioxidant functional food material. Pine bark extract is known to have an anti-inflammatory effect, to protect and improve skin and blood vessels, and to improve hypercholesterolemia, and a high dose of pine bark extract improves psoriasis. In this study, we conducted a pilot clinical trial to evaluate the effect of pine bark extract on the skin condition and serum lipid levels of patients with psoriasis. Patients with mild to moderate psoriasis who are receiving continual and who gave informed were enrolled in this study. As a result, the Psoriasis Area Severity Index significantly decreased from 8.0±10.3 to 5.8±7.4 ( p <0.01). Total serum cholesterol level decreased to 208.1±29.6 from 216.8±24.2 ( p <0.05; as an observed analysis). Pine bark extract may improve the skin condition and serum total cholesterol level of psoriasis patients. The limitation of this study is a small sample size and open testing.
{"title":"The Effects of Pine Bark Extract (Flavangenol®) on the Clinical Treatment and Serum Lipid Levels of Patients with Psoriasis","authors":"S. Imafuku, Bunji Koga, K. Itou, H. Ihara, T. Kamiya, Kinya Takagaki, Nobutaka Kusaba","doi":"10.3812/jocd.36.731","DOIUrl":"https://doi.org/10.3812/jocd.36.731","url":null,"abstract":"Psoriasis is a chronic inflammatory skin disease. While the etiology of psoriasis is not yet clear, environme-ntal factors such as food or eating habits are considered important aspects. Pine bark extract (Flavangenol Ⓡ ) is a polyphenol-rich antioxidant functional food material. Pine bark extract is known to have an anti-inflammatory effect, to protect and improve skin and blood vessels, and to improve hypercholesterolemia, and a high dose of pine bark extract improves psoriasis. In this study, we conducted a pilot clinical trial to evaluate the effect of pine bark extract on the skin condition and serum lipid levels of patients with psoriasis. Patients with mild to moderate psoriasis who are receiving continual and who gave informed were enrolled in this study. As a result, the Psoriasis Area Severity Index significantly decreased from 8.0±10.3 to 5.8±7.4 ( p <0.01). Total serum cholesterol level decreased to 208.1±29.6 from 216.8±24.2 ( p <0.05; as an observed analysis). Pine bark extract may improve the skin condition and serum total cholesterol level of psoriasis patients. The limitation of this study is a small sample size and open testing.","PeriodicalId":17355,"journal":{"name":"Journal of The Japan Organization of Clinical Dermatologists","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75967069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Condyloma acuminatum of the nipple resembling seborrheic keratosis","authors":"K. Murao, Y. Kubo","doi":"10.3812/jocd.36.35","DOIUrl":"https://doi.org/10.3812/jocd.36.35","url":null,"abstract":"","PeriodicalId":17355,"journal":{"name":"Journal of The Japan Organization of Clinical Dermatologists","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81472404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Analysis of 514 cases of the treatment of acute herpes zoster in the past 3 years: Relationship between the onset of postherpetic neuralgia and Amenalief® 400 mg","authors":"Toshitsugu Sato","doi":"10.3812/jocd.36.395","DOIUrl":"https://doi.org/10.3812/jocd.36.395","url":null,"abstract":"","PeriodicalId":17355,"journal":{"name":"Journal of The Japan Organization of Clinical Dermatologists","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74882354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Aggregation data of inpatients with onychomycosis in Akita National Hospital","authors":"N. Maki, A. Ishida, T. Demitsu","doi":"10.3812/jocd.36.388","DOIUrl":"https://doi.org/10.3812/jocd.36.388","url":null,"abstract":"","PeriodicalId":17355,"journal":{"name":"Journal of The Japan Organization of Clinical Dermatologists","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75701089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Improved detection of the dermoscopic structures of pigmented mucosal lesions using high-dynamic-range image conversion","authors":"Toshitsugu Sato, Masaru Tanaka","doi":"10.3812/jocd.36.39","DOIUrl":"https://doi.org/10.3812/jocd.36.39","url":null,"abstract":"","PeriodicalId":17355,"journal":{"name":"Journal of The Japan Organization of Clinical Dermatologists","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88494448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A child with Henoch-Schönlein purpura successfully treated with diaphenyl sulfone","authors":"K. Shimizu, M. Kawase, T. Etoh","doi":"10.3812/jocd.35.514","DOIUrl":"https://doi.org/10.3812/jocd.35.514","url":null,"abstract":"","PeriodicalId":17355,"journal":{"name":"Journal of The Japan Organization of Clinical Dermatologists","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78432022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"日本人尋常性乾癬患者に対するカルシポトリオール／ベタメタゾンジプロピオン酸エステルの配合ゲル剤の有効性および安全性の検討（国内第III相臨床試験）","authors":"Hidemi Nakagawa, Kazuo Isomae, T. Etoh","doi":"10.3812/JOCD.35.51","DOIUrl":"https://doi.org/10.3812/JOCD.35.51","url":null,"abstract":"","PeriodicalId":17355,"journal":{"name":"Journal of The Japan Organization of Clinical Dermatologists","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83325193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
For the treatment of onychomycosis, only oral drugs and topical medications not specifically indicated for this disease were available until a specific topical drug was released. In September 2014, a topical drug for onychomycosis was first marketed in Japan (efinaconazole: Clenafin Ⓡ ), and clinical results concerning its use for one year or longer have not yet been reported. We investigated 484 patients who were prescribed efinaconazole for treatment of onychomycosis at our department. Among the patients in whom cure was achieved, treatment for one year or longer was required in more than 30%, and the overall cure rate was 14.9% in the actual clinical setting. Among all patients, 81.3% showed improvement to some extent (including cure). With regard to safety, there were no systemic adverse reactions, while contact dermatitis was observed in 13 out of 484 patients. The launch of efinaconazole, which causes fewer adverse reactions, has provided an option for patients who would not show an adequate response to conventional treatments. In particular, this drug can be a first-line treatment for elderly patients and those using multiple oral medications. However, good patient adherence is crucial for a successful outcome, as well as assiduous management by the physician at the time of treatment initiation. A detailed explanation about the realistic prospect of cure should also be provided.
{"title":"Clinical use of the topical nail liquid efinaconazole in 484 patients with onychomycosis including long-term cases.","authors":"M. Inami, A. Igarashi","doi":"10.3812/jocd.35.748","DOIUrl":"https://doi.org/10.3812/jocd.35.748","url":null,"abstract":"For the treatment of onychomycosis, only oral drugs and topical medications not specifically indicated for this disease were available until a specific topical drug was released. In September 2014, a topical drug for onychomycosis was first marketed in Japan (efinaconazole: Clenafin Ⓡ ), and clinical results concerning its use for one year or longer have not yet been reported. We investigated 484 patients who were prescribed efinaconazole for treatment of onychomycosis at our department. Among the patients in whom cure was achieved, treatment for one year or longer was required in more than 30%, and the overall cure rate was 14.9% in the actual clinical setting. Among all patients, 81.3% showed improvement to some extent (including cure). With regard to safety, there were no systemic adverse reactions, while contact dermatitis was observed in 13 out of 484 patients. The launch of efinaconazole, which causes fewer adverse reactions, has provided an option for patients who would not show an adequate response to conventional treatments. In particular, this drug can be a first-line treatment for elderly patients and those using multiple oral medications. However, good patient adherence is crucial for a successful outcome, as well as assiduous management by the physician at the time of treatment initiation. A detailed explanation about the realistic prospect of cure should also be provided.","PeriodicalId":17355,"journal":{"name":"Journal of The Japan Organization of Clinical Dermatologists","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81300837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A case of bullous pemphigoid confined to umbilical region suspect of fixed drug eruption.","authors":"M. Ota, Yoshie Ehara, S. Nishimoto, Yasuki Hata","doi":"10.3812/JOCD.35.610","DOIUrl":"https://doi.org/10.3812/JOCD.35.610","url":null,"abstract":"","PeriodicalId":17355,"journal":{"name":"Journal of The Japan Organization of Clinical Dermatologists","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91539825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：